BVF Partners LP has recently announced that it has increased stake in Kymera Therapeutics Inc. (NASDAQ:KYMR) by 13.38%. After grabbing 4.69 million shares, the institutional investor is now in possession of 0.55 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.58% having worth around $142.37 million. Moreover, Redmile Group LLC increased its share by 0.27 million to have a control over 2.88 million shares. And BlackRock Fund Advisors raised its holdings to 0.15 million shares by acquiring 2.67 million shares or 4.88% of the stake.
Kymera Therapeutics Inc. (KYMR) concluded trading on 11/23/22 at a closing price of $27.22, with 0.48 million shares of worth about $13.01 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 88.50% during that period and on Wednesday the price saw a loss of about -2.82%. Currently the company’s common shares owned by public are about 54.54M shares, out of which, 50.98M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 75 times over the past 12 months. They bought 1,761,759 shares in 42 of the transactions. In 33 selling transactions, insiders dumped 650,404 shares.
T Rowe Price New Horizons Fund, SPDR S&P Biotech ETF, and T Rowe Price Small Cap Value Fund are the top 3 mutual funds which are holding stakes in Kymera Therapeutics Inc. T Rowe Price New Horizons Fund is currently holding 2.24 million shares of worth totaling $67.81 million. The company recently came buying 0.51 million shares which brought its stake up to 4.09% of the company’s outstanding shares. SPDR S&P Biotech ETF bought 11720.0 shares, after which its hold over company’s outstanding shares expand to 3.87%, leaving 2.12 million shares with the mutual fund that have a worth of about $64.26 million. T Rowe Price Small Cap Value Fund, after selling 0.98 million shares, have now control over 1.79% of the stake in the company. It holds 4000.0 shares of worth $29.67 million.
Kymera Therapeutics Inc. (NASDAQ: KYMR) started trading at $27.85, below -$0.16 from concluding price of the previous day. However, the stock later moved at a day high price of 28.41, or with a loss of -2.82%. Stock saw a price change of -6.75% in past 5 days and over the past one month there was a price change of 6.91%. Year-to-date (YTD), KYMR shares are showing a performance of -57.13% which decreased to -50.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $13.15 but also hit the highest price of $66.45 during that period. The average intraday trading volume for Kymera Therapeutics Inc. shares is 648.45K. The stock is currently trading -6.90% below its 20-day simple moving average (SMA20), while that difference is up 6.50% for SMA50 and it goes to -2.44% lower than SMA200.
BVF Partners LP acquired 4.69 million shares of Kymera Therapeutics Inc. having value of about $142.37 million. Data submitted at the U.S SEC by BVF Partners LP revealed that the firm now holds 0.55 million shares in the company valued at close to $15075688.12, or have control over 13.38% stake in the company. Kymera Therapeutics Inc. (NASDAQ: KYMR) currently have 54.54M outstanding shares and institutions hold larger chunk of about 98.80% of that. Holding of mutual funds in the company is about 37.04% while other institutional holders and individual stake holders have control over 45.09% and 20.52% of the stake respectively.
The stock has a current market capitalization of $1.45B. It has posted earnings per share of -$2.94 in the same period. It has Quick Ratio of 5.40 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KYMR, volatility over the week remained 5.40% while standing at 7.22% over the month.
Analysts are in expectations that Kymera Therapeutics Inc. (KYMR) stock would likely to be making an EPS of -$0.74 in the current quarter, while forecast for next quarter EPS is -$0.55 and it is -$2.92 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.03 which is -$0.44 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.56 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -70.00% while it is estimated to increase by 0.30% in next year.
Analysts at 18 brokerage firms have issued recommendations for the Kymera Therapeutics Inc. (KYMR)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.10. Out of those 18 Wall Street analysts, 13 recommended a “Buy” rating, while 5 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Coverage by Jefferies stated Kymera Therapeutics Inc. (KYMR) stock as a Buy in their note to investors on August 15, 2022, suggesting a price target of $40 for the stock. On August 03, 2022, Goldman Initiated their recommendations, while on July 20, 2022, SVB Leerink Initiated their ratings for the stock with a price target of $26. Stock get an Outperform rating from Credit Suisse on April 28, 2022.